JP2020143072A5 - - Google Patents

Download PDF

Info

Publication number
JP2020143072A5
JP2020143072A5 JP2020077160A JP2020077160A JP2020143072A5 JP 2020143072 A5 JP2020143072 A5 JP 2020143072A5 JP 2020077160 A JP2020077160 A JP 2020077160A JP 2020077160 A JP2020077160 A JP 2020077160A JP 2020143072 A5 JP2020143072 A5 JP 2020143072A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutically acceptable
acceptable salt
predopidine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020077160A
Other languages
English (en)
Japanese (ja)
Other versions
JP7035108B2 (ja
JP2020143072A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020143072A publication Critical patent/JP2020143072A/ja
Publication of JP2020143072A5 publication Critical patent/JP2020143072A5/ja
Application granted granted Critical
Publication of JP7035108B2 publication Critical patent/JP7035108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020077160A 2014-06-30 2020-04-24 プリドピジンの類似体、それらの製造および使用 Active JP7035108B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462019337P 2014-06-30 2014-06-30
US62/019,337 2014-06-30
US201462076436P 2014-11-06 2014-11-06
US62/076,436 2014-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017520772A Division JP6800842B2 (ja) 2014-06-30 2015-06-29 プリドピジンの類似体、それらの製造および使用

Publications (3)

Publication Number Publication Date
JP2020143072A JP2020143072A (ja) 2020-09-10
JP2020143072A5 true JP2020143072A5 (https=) 2020-11-26
JP7035108B2 JP7035108B2 (ja) 2022-03-14

Family

ID=54929343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017520772A Active JP6800842B2 (ja) 2014-06-30 2015-06-29 プリドピジンの類似体、それらの製造および使用
JP2020077160A Active JP7035108B2 (ja) 2014-06-30 2020-04-24 プリドピジンの類似体、それらの製造および使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017520772A Active JP6800842B2 (ja) 2014-06-30 2015-06-29 プリドピジンの類似体、それらの製造および使用

Country Status (17)

Country Link
US (4) US10130621B2 (https=)
EP (2) EP3160470B1 (https=)
JP (2) JP6800842B2 (https=)
CN (2) CN106456618A (https=)
AU (1) AU2015284385B2 (https=)
BR (1) BR112016030968B1 (https=)
CA (1) CA2951494C (https=)
DK (1) DK3160470T3 (https=)
EA (1) EA201790101A1 (https=)
ES (1) ES2927888T3 (https=)
HU (1) HUE060242T2 (https=)
IL (2) IL249601B (https=)
MX (1) MX382649B (https=)
PL (1) PL3160470T3 (https=)
TW (1) TW201613859A (https=)
UY (1) UY36192A (https=)
WO (1) WO2016003919A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶(pridopidine)之氫溴酸鹽
US11090297B2 (en) * 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) 2017-08-14 2026-01-30 Prilenia Neurotherapeutics Ltd. Zdravljenje amiotrofične lateralne skleroze s pridopidinom
CA3073568A1 (en) 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
AU2020243692B2 (en) * 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
CN121243170A (zh) 2019-06-12 2026-01-02 普瑞尼亚神经治疗有限公司 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物
CA3176917A1 (en) * 2020-05-04 2021-11-11 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective s1r agonist
MX2023004516A (es) * 2020-10-20 2023-05-04 Prilenia Neurotherapeutics Ltd Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
IL307462A (en) * 2021-04-14 2023-12-01 Prilenia Neurotherapeutics Ltd Treatment of prodromal huntington disease
JP7829678B2 (ja) * 2021-10-11 2026-03-13 プリレニア ニューロセラピューティクス リミテッド 神経変性眼疾患を治療するためのプリドピジン及びその類似体
CN114716391B (zh) * 2022-04-24 2023-12-12 杭州仟源保灵药业有限公司 一种醋甲唑胺杂质及其制备方法和应用
EP4519246A4 (en) * 2022-05-03 2025-08-13 Prilenia Neurotherapeutics Ltd PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE
CN118924710A (zh) * 2024-08-05 2024-11-12 四川大学 细辛脑在制备治疗和/或预防眼部疾病药物中的应用和一种组合物及其应用
WO2026035949A1 (en) * 2024-08-08 2026-02-12 Prilenia Therapeutics Inc. Combination of pridopidine and low dose anti-dopaminergic medication (adm) for treating huntington disease and sympto thereof
WO2026080658A1 (en) 2024-10-10 2026-04-16 Prilenia Therapeutics Inc. Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6472736A (en) 1987-09-14 1989-03-17 Toshiba Corp Mri apparatus
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
ATE449071T1 (de) * 2004-06-08 2009-12-15 Nsab Af Neurosearch Sweden Ab Neue substituierte piperidine als modulatoren der dopamin neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2578750A1 (en) * 2004-09-04 2006-03-16 Teva Pharmaceutical Industries, Ltd. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
EP1807394A1 (en) * 2004-10-13 2007-07-18 Neurosearch Sweden AB Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
CA2584831C (en) * 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1716139A1 (en) * 2005-01-03 2006-11-02 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
WO2008155357A2 (en) * 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶(pridopidine)之氫溴酸鹽
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
MX2015003608A (es) 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
US20150216850A1 (en) 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
EP4516356A3 (en) * 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline

Similar Documents

Publication Publication Date Title
JP2020143072A5 (https=)
JP2021119186A5 (https=)
JP2025013344A5 (https=)
JP2009506014A5 (https=)
US20060264512A1 (en) Method for the treatment of sexual dysfunction due to medical conditions
US20080119482A1 (en) Method for the treatment of attention deficit hyperactivity disorder
JP2011068653A5 (https=)
US20080199518A1 (en) Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
JP2014532638A5 (https=)
JP2010511616A5 (https=)
JP2009537538A5 (https=)
JP2012255026A5 (https=)
US20050239798A1 (en) Method for the treatment of premenstrual and other female sexual disorders
US20230190726A1 (en) Compositions and methods for treating negative symptoms in non-schizophrenic patients
CA2687741A1 (en) Stabilized amorphous forms of imatinib mesylate
AU2009288820A1 (en) Combination therapy for tuberculosis
JP2010512413A5 (https=)
RU2007147427A (ru) Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
JP2023089012A5 (https=)
IL264349B2 (en) Regimen comprising neratinib for the treatment of cancer
EP3400942B1 (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
TW201822769A (zh) 用於治療非小細胞肺癌之egfr t790m 抑制劑及cdk抑制劑之組合
JP2015503579A5 (https=)
JP2012526766A5 (https=)
JP2005506982A5 (https=)